NNC6019-0001

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Drug Information

Target Indication

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Clinical Trial

Last updated: 1/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVO

Novo Nordisk A/S

Related Pipeline

Congenital Bleeding Disorder

Diabetes

Obesity

Obesity or Overweight

Diabetes

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts